Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Schmidt

Showing results (21-30 of 87) with videos related to

Pageof 9
Sort By:
Cancer Discovery|August 14, 2012
PARP inhibitors refocus for reboundCharles Schmidt
Cancer Discovery|July 13, 2012
A Myriad of questionsCharles Schmidt
Scientific American|March 17, 2026
Stopping an Autoimmune Attack : IgA nephropathy, a frequent cause of kidney failure, is underdiagnosed. New treatments mean it's more important now to find those who will benefitCharles Schmidt
Nature Biotechnology|September 14, 2023
Septerna: making another run on GPCRsCharles Schmidt
Environmental Health Perspectives|October 25, 2024
A Bigger Big Picture: Insights on Environmental Chemicals and Dyslipidemia through Combined "Omic" AnalysesCharles Schmidt
Nature Biotechnology|July 27, 2021
Publisher Correction: COVID-19 long haulersCharles Schmidt
Nature Biotechnology|June 19, 2024
Editor's pick: Tome BiosciencesCharles Schmidt
Nature Biotechnology|June 8, 2017
First deuterated drug approvedCharles Schmidt
Journal of the National Cancer Institute|April 21, 2005
Experts worry about chilling effect of federal regulations on treating painCharles Schmidt
Nature Biotechnology|July 14, 2021
COVID-19 long haulersCharles Schmidt
Pageof 9

Showing results (21-30 of 87) with videos related to

Sort By:
Pageof 9
Cancer Discovery|August 14, 2012
PARP inhibitors refocus for reboundCharles Schmidt
Cancer Discovery|July 13, 2012
A Myriad of questionsCharles Schmidt
Scientific American|March 17, 2026
Stopping an Autoimmune Attack : IgA nephropathy, a frequent cause of kidney failure, is underdiagnosed. New treatments mean it's more important now to find those who will benefitCharles Schmidt
Nature Biotechnology|September 14, 2023
Septerna: making another run on GPCRsCharles Schmidt
Environmental Health Perspectives|October 25, 2024
A Bigger Big Picture: Insights on Environmental Chemicals and Dyslipidemia through Combined "Omic" AnalysesCharles Schmidt
Nature Biotechnology|July 27, 2021
Publisher Correction: COVID-19 long haulersCharles Schmidt
Nature Biotechnology|June 19, 2024
Editor's pick: Tome BiosciencesCharles Schmidt
Nature Biotechnology|June 8, 2017
First deuterated drug approvedCharles Schmidt
Journal of the National Cancer Institute|April 21, 2005
Experts worry about chilling effect of federal regulations on treating painCharles Schmidt
Nature Biotechnology|July 14, 2021
COVID-19 long haulersCharles Schmidt
Pageof 9